Drug companies reach $2.15B settlement in patent-infringement case

06/13/2013 | Wall Street Journal, The

Takeda Pharmaceutical and Pfizer will receive a total of $2.15 billion as part of a settlement reached with generic-drug manufacturers in a patent-infringement case. The damages stem from an "at-risk" launch of a generic substitute for the heartburn drug Protonix. In an at-risk launch, a generic-drug company begins selling a generic medication while patent litigation is still underway. The strategy can backfire if a drug patent is later found to be valid, which is what happened in this case.

View Full Article in:

Wall Street Journal, The

Published in Brief: